H igh-quality clinical studies to define the need for plasma transfusion as prophylaxis in patients with abnormalities of conventional coagulation tests remain very challenging to design and conduct. One unanswered issue centers on the utility of conventional coagulation tests. For example, a recent systematic review was unable to identify values of coagulation tests, including the prothrombin time (PT) or international normalized ratio, required to support safe central venous catheterization. 1 It is also well recognized that the PT and activated partial thromboplastin time provide only a very limited assessment of hemostatic status, for several reasons: these include that the PT and activated partial thromboplastin time measure the time taken for a clot to form which occurs when only 5% of total thrombin generation (TG) has occurred, they reflect only the procoagulant factors and are unaffected by the levels of natural anticoagulants, they are insensitive to modest but clinically relevant low levels of procoagulant factors, and finally they are poor at identifying a prothrombotic state. [2] [3] [4] [5] Despite being some of the most frequently ordered hematology investigations in hospital practice, conventional coagulation tests may therefore have limited predictive value for clinical bleeding and the safety of invasive procedures, 6 and their role in indicating a need for plasma transfusion in nonbleeding patients remains unclear. [7] [8] [9] [10] With this in mind, interest has focused on different diagnostic assays. Alternative tests might provide more information on the summation of procoagulant activities or better address the net balance between procoagulant and anticoagulant forces. [11] [12] [13] [14] [15] One such test is TG, but there are very limited data in the setting of critical care admissions, which are by nature a very heterogeneous group of patients. This group of patients also presents the common scenario of abnormalities in conventional coagulation tests and consideration of need for plasma transfusion before procedures. In this study we identified and followed patients with a prolonged PT but who were not bleeding at the time of their admission to critical care, as this represents the subgroup of critically ill patients where uncertainty exists regarding the assessment of bleeding risk and the need for plasma transfusions. We were interested in comparing the results of TG assays with the PT ratio (PTR), platelet (PLT) count, and fibrinogen concentration. [11] [12] [13] [14] [15] [16] We therefore designed a pragmatic critical care study to determine whether TG did (or did not) provide additional information that could be clinically informative in defining points of intervention in further clinical studies. The primary study questions were to define the relationships between the PTR and hemostatic capacity assessed by TG (including endogenous thrombin potential [ETP], lag time, peak thrombin, and time to peak) and the relationship of both with the incidence of bleeding. A secondary aim was to determine whether combining these measures with PLT count and fibrinogen improved sensitivity or specificity for bleeding.
MATERIALS AND METHODS

Overview
In this observational study, all patients admitted to the participating intensive care units (ICUs) within the first 48 hours of admission had a screening log completed by the research team to identify patients eligible for study recruitment. Once consent was given by the patient (or if the patient was unable to consent with agreement from a personal consultee or clinician not directly involved with the study), a registration form was completed and initial or registration blood samples were taken as soon as possible and within the first 48 hours of the patient's ICU admission. A 48-hour period was allowed so that patients admitted at the weekend could be included in the study; however, all blood samples were taken as soon as practically possible after consent.
Patients and centers
Inclusion was defined by prolongation of the locally measured PT time by more than 3 seconds beyond the upper limit of the normal range within 48 hours of admission. This was a pragmatic decision to facilitate screening of patients for enrollment. For analysis, the PT was converted to PTR, based on local data for mean normal PT. The PTR triggering inclusion was similar for all centers (1.36 to 1.44). Although not validated for this purpose, the thromboplastins used at the four sites also had a very similar international sensitivity index close to 1 (range, 0.99-1.02) and inclusion based on international normalized ratio would be similar at all sites as well. Exclusion criteria were as follows: evidence of active clinical bleeding at the time of enrollment (active blood loss through postoperative drains or clinically significant bleeding, defined as either estimated total cumulative blood loss > 300 mL, or in a critical site, e.g., brain); warfarin therapy or other treatment dose anticoagulant therapy at time of enrollment; patients in whom a decision to withdraw or withhold critical care had been made (including patients with probable or proven brain death) within 4 hours after admission; and patients less than 16 years of age. Intensive care centers were general medical units, selected on the basis of laboratory support, with the ability to centrifuge blood samples within 2 hours of venipuncture.
Data collection and period of study
The baseline data collected at registration included age, sex, hospital and ICU admission date, most relevant ICU admission diagnosis, transfusion history, significant 
Blood sampling
Blood samples, drawn into 0.109 mol/L citrate, were taken at registration. Anonymized blood samples were labeled with a study patient identification number, date, and time and packaged in a study sample bag for transport to the local and then central laboratory for storage. The majority of patients had central venous access, peripherally inserted central cannulas (PICCs) or an arterial line in situ as this was part of routine management in intensive care. When access through a central line, PICC line, or arterial line was not possible, samples were collected by venipuncture. The brand of PICC line called "Power PICCs," which were locked with heparin (as access was not required during the day) were not considered suitable for sampling. Samples were also not taken from lines that had been used for heparin infusions or "blocked" and flushed with a fibrinolytic drug. To check for heparin contamination, an anti-Factor Xa level was performed on all samples in the laboratory.
Laboratory assessment
All laboratories followed a common standard operating procedure. Blood samples were double-centrifuged at 2500 3 g for 15 minutes to create PLT-poor plasma, which was frozen at -808C for shipping to the central laboratory for analysis. TG was measured in a central laboratory with the Thrombinoscope assay (Thrombinoscope BV). A combination of 5 pmol/L recombinant human tissue factor (Dade Behring) and 4 lmol/L phospholipid (Avanti Polar Lipids) were used as activators with the coagulation reaction triggered by the addition of calcium chloride in combination with Z-Gly-Gly-Arg-amino-methyl-coumarin, a thrombin-sensitive fluorogenic substrate (Thrombinoscope BV). Analysis was performed using a fluorescent microplate reader (Fluoroscan, Thermo Labsystems) and computer software (Thrombinoscope Version 5, Thrombinoscope BV). The Thrombinoscope software was used to convert the fluorescence signal into nmol/L thrombin activity with correction for the inner filter effect and thrombin bound to a-2-macroglobulin activity, as described by Hemker and colleagues.
11 Lag time, time to peak, peak thrombin activity, and ETP were extracted from the thrombograms.
Sample size
The study was not designed to test hypotheses about differences between two groups of patients, and so a power calculation was not considered relevant, but we determined the required number of patients to ensure that a 95% confidence interval (CI) for the "true proportion" of patients with a low ETP was sufficiently narrow. The sample size requirement was based on a true underlying proportion of 0.5 as this would lead to the largest sample size needed to obtain a sufficiently precise estimate of the proportion. Two-hundred samples with 100 "positives" of low ETP gives a 95% CI of approximately 67%. An earlier pilot study indicated that from 21 patients, measurement of TG in plasma was increased in 14 patients and normal or reduced in seven patients. During early recruitment, more patients than expected (approx. 32%) were identified to have liver disease; since one goal of the study was to understand the abnormalities in coagulation in a broader general ICU population, the sample size was increased to ensure that approximately 200 patients without liver disease were recruited.
Analysis plan
We explored risk of bleeding by several ways, in the absence of a universal gold standard. We presented bleeding events by stepwise abnormalities, by PTR of less than 2, 2.0 to less than 2.5, 2.5 to less than 3.0, and 3 or more, reflecting this as common clinical practice. We also reviewed the results of our earlier national survey 21 and the results from a local survey of responses by critical care intensivists to different case scenarios, which suggested that the decision to use prophylactic plasma transfusion was additionally influenced by changes (reductions) in PLT count and fibrinogen, as well as by PTR. Therefore, in this study we presented descriptive results on bleeding events according to groups incorporating changes in fibrinogen and PLT count alongside PTR (PTR < 2, fibrinogen > 2 g/L, and PLT count > 100 3 10 9 /L; PTR < 2 and either fibrinogen 2g/L or PLT count 100 3 10 9 /L; PTR 2, fibrinogen > 2 g/L, and PLT count > 100 3 10 9 /L; PTR 2 and either fibrinogen 2g/L or PLT count 100 3 10 9 /L). We also predefined stepwise abnormalities for TG. TG reference ranges were derived from 30 normal volunteers and defined as the mean 6 2 standard deviations (SDs). Bleeding events were then grouped according to the following TG categories: low (ETP < 1121 nmol/L/min, lag time > 3.2 min, peak < 202 nmol/L, and time to peak > 6.7 min); normal; or high (ETP 1816 nmol/L/min, lag time-< 1.8 min, peak > 372 nmol/L, and time to peak < 3.9 mins). For the purposes of this paper, these categories will be described as "low TG" and "high TG" or, for example, ETP-low or ETP-high.
We reported an initial descriptive analysis of the data, using both numerical summaries (means and SDs for continuous data, medians and interquartile ranges [IQRs] for skewed continuous data, frequencies and percentages for discrete variables) and graphical displays. This covered baseline characteristics of enrolled patients, and the spread of abnormalities of hemostatic measures in the 306 patient study group enrolled into the study. We presented data on the numbers of patients in each of the hemostatic (TG) groups for each of the variables of TG: for example "ETP-low," "normal," or "ETP-high," based on the ETP thresholds above. We assessed whether the TG results for the four bleeding risk groups and for those who received plasma were statistically different using analysis of variance. We also analyzed the results for patients with liver disease. Student's t tests were used to compare mean values for patients who had a bleeding episode with those who did not and Kruskal-Wallis tests to compare median values. Spearman's rank correlation was used to explore associations. Receiver operating characteristic (ROC) curves were used to assess the ability of TG results and PTR to discriminate between those patients who had a bleed and those who did not. All analyses were undertaken in computer software (SAS, Version 9.4, SAS Institute, Inc.). A significance level of 5% was used to indicate significance.
RESULTS
Characteristics of patients
Patients were recruited across four ICUs. A total of 1457 patients were screened and identified with a local prolonged PT of more than 3 seconds above local reference range for study enrollment. A total of 306 patients were enrolled. The main reasons for exclusion were active bleeding (n 5 128), on anticoagulants (n 5 289), expected duration on ICU was short before transfer to ward (n 5 203), out of working hours or lack of research nurse availability (n 5 140), cases where care was being withheld or inappropriate to approach (n 5 129), and lacking consent (n 5 101). Table 1 presents the baseline characteristics of all 306 patients recruited for blood sampling across all four centers. A total of 107 (35%) patients had received blood components in the 24 hours before admission, of which 69 of 107 received red blood cells (RBCs), 69 of 107 fresh-frozen plasma, 42 of 107 PLTs, and 18 of 107 cryoprecipitate. Forty patients had been taking anticoagulants or anti-PLT agents (unfractionated heparin, lowmolecular-weight heparin, aspirin) before admission, but not at enrollment. In the preceding 24 hours, mean values for all patients were hemoglobin concentration 96 
The nature and types of clinical bleeding
There were a total of 101 bleeding events developing in 46 patients during the period of observation after registration. Twenty events were classified as major bleeds and 81 moderate/minor; 14 patients developed a major and another bleed on the same day. The 20 major bleed events included 14 cases with blood loss recorded as more than 300 mL, five bleeds at critical sites (two intracranial, two retroperitoneal, and one intraarticular), and three woundrelated bleeds, which required intervention (with need for RBC transfusion for active bleeding); two patients each had two major bleed sites reported for a major bleed event. The 81 other bleed events were experienced by 44 patients and included 51 events that were procedure related. Of the 81 events, 56 were associated with a single bleeding site, 20 with two bleeding sites, and five with three sites. These 81 bleeds were classified as line related (cannula n 5 3; PICC n 5 1; arterial n 5 11; large-vessel, e.g., subclavian, jugular n 5 5; other insertion sites, e.g., femoral n 5 14); drain and wound related (incision site n 5 16; drains, e.g., chest n 5 12; feeding tube n 5 7; wound n 5 1); intestinal (melena n 5 7; hematemesis n 5 2; fresh rectal bleeding n 5 1); skin and mucosal (bruising n 5 6; oral/nasal n 5 4); and respiratory related (endotracheal tube n 5 8; tracheostomy n 5 4; chest drain n 5 1; other/mixed n 5 9).
The relationship between PTR and variables of TG
In total, registration samples were analyzed from 256 patients with TG data available. There was a wide range of results for the TG variables (ETP, lag time, time to peak, and peak), which are shown in comparison with the PTR (Fig. 1) . Although the PT was, by definition, prolonged in the study group, many patients had TG variables that were within the normal range or even elevated. Although some patients had a reduction in ETP or peak thrombin these were present over a wide range of PTR. The association with ETP is shown in Fig. 1A and the Spearman rank correlation was -0.257 (p < 0.0001). The differences and poor correlation between the TG variables and PTR suggest that they are measuring different aspects of the coagulation process. Overall, PTR appears a poor predictor of TG.
A similar result was obtained when we examined the coagulation results as categories (251 patients). At registration 111 were ETP-low (1121 nmol/L/min; 44.2%), and 20 were ETP-high (1816 nmol/L/min; 8.0%); the remaining 120 patient samples were within normal limits (47.8%). Overall, 40% (65/161) of patients with PTR of less than 2, 40% (17/42) of patients with PTR of 2.0 to less than 2.5, 45% (9/20) of patients with PTR 2.5 to less than 3.0, and 71% (17/24) of patients with PTR of 3 or more were ETPlow. ETP-high was found in 9% (14/161) of patients with PTR of less than 2 and 12% (5/42) of patients with PTR of 2.0 to less than 2.5. Again there is little relationship between prolongation of the PT and variables of TG.
Descriptive data on the clinical characteristics of those patients according to ETP is shown in Fig. 2 . Some differences in ETP may reflect patient factors, such as "route of admission" (admission from emergency department that includes trauma may show more frequently as hypercoagulable); by contrast, patients with lower APACHE II scores appeared less commonly as hypercoagulable. However, there was evidence of considerable variation across all groups.
For the 79 patients with liver disease, ETP-low was identified in 24 of 48 patients (50%) with PTR of less than 2, five of 13 patients (38%) with PTR of 2.0 to less than 2.5, three of seven patients (43%) with PTR of 2.5 to less than 3.0, and nine of 11 patients (82%) with PTR of 3 or more. By comparison, for 166 patients without liver disease, the corresponding figures were 36, 41, 42, and 62%, respectively. The differences suggest that in the presence of liver disease, TG more readily detects a hypocoagulable state in those patients with PTR of less than 2 (Fig. 3 plots) . Plots for all variables of TG are shown in Fig. S1 (available as supporting information in the online version of this paper). Table S1 (available as supporting information in the online version of this paper) presents the full information on abnormalities of PT, PTR fibrinogen, and variables of TG by baseline characteristics at registration. While evidence of changes in PTR and TG can be seen across a number of categories (e.g., decrease in PTR with increasing age), it is recognized that additional confounding factors will apply, for example, reasons for admission and frequency and severity of comorbidities, which will also change with age. The values for ETP and lag time are also shown by comparison to the results for categories of severity of PTR alone or by PTR in combination with results for PLT count and fibrinogen level (Table S2 , available as supporting information in the online version of this paper).
Exploring the prediction of PTR or ETP to predict bleeding
At registration, 65% of patients had a PTR of less than 2, 17% 2 to less than 2.5, 8% 2.5 to less than 3.0, and 10% 3 or more. Major and/or other bleeds were represented in all categories of PTR and there was an approximately equal distribution of bleeding events according to PTR of more than or less than 2 ( Table 2 , top rows; a trend for more minor bleeds when PTR > 2 was noted). The median PTR at registration for patients who bled (1.96; IQR, 1.11; n 5 46) was not different compared to patients who did not bleed (1.78; IQR, 0.48; n 5 255; p 5 0.0713). Therefore, categorization of PTR does not readily predict bleeding risk. Table 2 also shows the distribution of bleeding events when bleeding and TG are considered in categories. As for PTR analyses, the distribution of bleeding events was wide across all TG categories and categorization of TG variables in this way appears not to be useful for prediction of bleeding. However, we note that no bleeding events were documented in the group predefined as showing ETPhigh at registration, although the difference for mean ETP at registration for patients who bled (1133.6; SD, 308.8; n 5 38) compared to patients who did not bleed (1236.6; SD, 438.0; n 5 213; p 5 0.17) did not reach levels of significance. The lack of potential discriminatory effect on risk of bleeding remained apparent when patients with low PLT count were excluded, to allow for any confounding of PLT effect on a comparison between TG and PTR, although a trend for lag time and peak thrombin did emerge (Table S3 , available as supporting information in the online version of this paper).
Receiver operating characteristic curves were also constructed for all the variables to determine the relative utility of the PTR and the TG for prediction of bleeding. None of the TG variables nor the PTR showed a useful predictive relationship with bleeding (area under the curve, c values varied 0.52 to 0.63; data not shown). Finally, the results for prediction of bleeding were represented in a flow chart for different threshold levels of TG ETP, PLT count, and fibrinogen (Fig. 4) . This figure illustrates the broad distribution of numbers of patients who bled by categories of TG ETP, fibrinogen, and then PLT count. Of additional interest, this suggests that high ETP is associated with less bleeding risk, but that patients with normal ETP, fibrinogen level of more than 2 g/L, and PLT count of more than 100 3 10 9 /L may also have a reduced risk of bleeding.
DISCUSSION
This study presents exploratory analysis of the ability of PTR and TG to predict bleeding across a heterogeneous group of nonbleeding patients admitted to critical care units. Although the PT was prolonged in all study enrollments, the TG variables suggested that many patients had normal thrombin-generating capacity. Overall, 120 patients, despite prolonged PT, had normal ETP; indeed in some patients it was increased. Despite seemingly significant degrees of PTR prolongation, the findings for ETP, as a key component of TG, suggested that reasonable levels of hemostatic capability were retained in a significant number of patients. This supported the study hypothesis that prolongation of PT does not give an accurate estimation of an individual's coagulation potential. Moreover, there was only weak correlation between increasing PTR and decreasing ETP, or indeed all other variables of TG, indicating that they provide distinct measures of hemostatic capacity. However, the suggestion that this may translate into better prediction of bleeding was not borne out by the further analyses including ROC, which showed little evidence for a particular TG variable that could identify a higher risk of bleeding.
Some patients in our study demonstrated more extreme changes in TG or ETP variables, including what might be considered hypocoagulopathy or hypercoagulopathy. These patients could not readily be identified by different baseline characteristics or by PT, although features including recent admission from emergency departments or severity of illness on ICU may be relevant. In this context, it is recognized that trauma and severe illness are prothrombotic. 22, 23 By comparison, patients with liver disease may be more associated with ETP-low or peak thrombin-low figures (Fig. 3) . This patient population has been extensively investigated and TG has been used to indicate balanced hemostasis in patients with chronic liver disease, but this required addition of thrombomodulin, which was not performed in our study. 12, 13 There was no evidence that ETP-low patients were overrepresented compared to patients with less degrees of abnormality of PTR in those groups defined by reductions in PLT count and fibrinogen level beyond that provided by presentation of PTR results alone.
Overall, TG appears to provide quite different assessment of hemostatic potential from the PTR. TG provides a functional test of the plasmatic coagulation system in (PLT-poor) plasma. However, any usefulness of TG to provide clinically relevant information on bleeding risk was not directly supported by the findings of our exploratory study; rates of patients developing bleeding events appeared similar across all different categories of PTR and TG including ETP.
Further study is warranted given the preliminary nature of the results for the study limitations and the nature of variability for TG despite all patients demonstrating abnormal PTR, including specifically those identified as ETP-high (and potentially hypercoagulable). 24 We do not know whether the concentration of TG used in this study was the optimum for detecting useful difference. Moreover, we did not include thrombomodulin in these assays and so the contribution of the protein C-protein S system was not assessed either. This may be an important variable in liver disease, for example. Finally, there are different variables to TG, and it is of interest that lag time, for example, did not show the same changes as seen for ETP. This suggests that additional work needs to explore different features of TG and their origins. Other limitations relate to the heterogeneity of the patient population in critical care and bleeding events and recognizing that the significance of 3-second prolonged PT was not identical among centers (e.g., reagent variables).
In conclusion, there remains a need for better tests to determine whether interventions can be withheld safely in groups of nonbleeding patients with prolonged PTR to provide a rationale that would avoid complications of transfusion of plasma [25] [26] [27] and avoid delays in interventional procedures such as line insertions and tracheostomies, which normally require ordering, transport, and administration of plasma and permit reallocation of resources. Prospective research may need to consider modification of the calibrated automated thrombography including addition of thrombomodulin and concentration of TG and to explore combining TG with other variables such as clinical subgroups, for example, liver disease (Fig.  3) ; presence of inflammation; and PLTs, fibrinogen, and hematocrit. Further studies could also explore some of the hypotheses generated by our study, such as a role for ETPhigh to predict reduced bleeding risk despite an abnormal PTR or a possibly useful trend in lag time and peak thrombin when patients with thrombocytopenia were excluded. We were also unable to gain more information by combining TG with PLT count or fibrinogen level in this study. The need for such studies also recognizes that the PTR has never been validated formally in critical care or indeed other clinical settings outside inherited factor deficiencies or warfarin overanticoagulation. Future clinical studies to define a need for interventions such as plasma transfusion in nonbleeding patients need to consider the value of the diagnostic tests used to assess hemostatic competence.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article. Table S1 . Blood results by baseline characteristics at registration. Results expressed as mean (standard deviation) n for normally distributed data and median (Q1-Q3) n for skewed data. APACHE II 5 Acute Physiology and Chronic Health Evaluation II score, ICNARC 5 Intensive Care National Audit and Research Centre. Table S2 . Data for endogenous thrombin potential (ETP) and lagtime in categories at registration for all patients, shown by increasing severity of prothrombin time ratio (PTR) and alongside changes in fibrinogen and platelet count. There was a statistically significant difference between the four mean ETP values for groupings by PT alone, p 5 0.0210 and between the four mean ETP values for grouping including platelet count and fibrinogen, p 5 0.0112. There were no significant differences for lag time between the four median lag times in either grouping. Data for mean peak times, and mean time to peak values were also available. There was a statistically significant difference between the four mean peak times, but no significant changes for median time to peak times for both groupings (data not shown). There were a small proportion of missing analyses for all categories (data not shown). Further analysis of patients with liver disease for the different parameters of TG and the relationships with PTR corresponded with the findings for all patients, the differences between the four mean ETP values for groupings by PT in conjunction with abnormalities of fibrinogen and platelet count was again significant, although this did not reach statistical significance when analysed by PTR groupings alone (data not shown). Table S3 . Bleed severity for the 32 patients who bled, by the different parameters of TG, after excluding patients with severe thrombocytopenia, showing the percentage of patients who bled in each TG category Fig. S1 . Box plots for the TG variables of highest PTR, fibrinogen, and lagtime by PTR category and by liver disease or not, with the reference range for the TG variable shown as dotted lines
